Acurx Pharmaceuticals is registering up to 1,500,000 common shares for resale by Lincoln Park Capital Fund, LLC, with potential company sales generating up to $2.8 million in gross proceeds. The company would direct proceeds from its own sales to working capital, research and development, and general corporate expenses.
Key Highlights
- Lincoln Park Capital Fund, LLC could offer 1,500,000 Acurx common shares for resale.
- Acurx’s potential proceeds would come from separate sales to Lincoln Park under the purchase agreement.
- The ownership table lists Lincoln Park Capital Fund, LLC with 409,789 shares before the offering.
Up to 1,500,000 shares of common stock (1.5 million) may be resold by Lincoln Park Capital Fund, LLC under Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) prospectus terms. Acurx is not selling shares through the resale.
Lincoln Park Resale Block
The registered shares are common stock with a $0.001 par value. Lincoln Park may sell the securities from time to time, with the price determined by the prevailing Market Price or through negotiated transactions. The shares consist of stock already issued or potentially issuable to Lincoln Park under a purchase agreement dated May 8, 2025. Acurx will receive no money from Lincoln Park’s resale of shares covered by the prospectus. Lincoln Park, rather than Acurx, is responsible for its selling and other expenses.
Potential $2.8M Company Proceeds
That amount is separate from the $9.2 million previously received through sales under the purchase agreement. The company may sell less than the full $2.8 million. The prospectus also states that the beneficial ownership cap could prevent Acurx from selling the entire amount, in which case total aggregate gross proceeds under the purchase agreement would be less than $12 million. The actual number of shares issued in company sales will vary with the sales prices. Acurx may also choose not to sell any shares under the agreement.
Working Capital And Research
Net proceeds from Acurx’s own sales to Lincoln Park are intended for Working Capital and general corporate purposes. The company has broad discretion over how those net proceeds are allocated and has not assigned a specific amount to each purpose. Its stated plans also allow proceeds to be used for other purposes if that becomes necessary or advisable. Pending deployment, Acurx expects to place net proceeds in interest-bearing marketable securities.
Share Count And Ownership Terms
Assuming all 1,500,000 registered shares are issued, Acurx would have 7,059,405 shares outstanding immediately afterward. That figure is based on 5,559,405 common shares outstanding as of August 31, 2026. The ownership table lists Lincoln Park Capital Fund, LLC with 409,789 shares before the offering. Its holdings include 70,738 common shares, 9,017 shares issuable upon exercise of pre-funded warrants, and 330,034 shares issuable upon exercise of Series H warrants. The prospectus excludes the registered shares from Lincoln Park’s pre-offering beneficial ownership calculation because issuance and sales remain at Acurx’s discretion and depend on conditions outside Lincoln Park’s control. The purchase agreement also limits the amounts that may be sold at any time, including through the beneficial ownership cap. Separately, the assumed post-offering share count excludes 2,565,549 shares issuable upon outstanding Warrant exercises, 348,625 shares issuable upon stock-option exercises, 106,947 shares reserved for future awards under the 2021 Equity Incentive Plan, and 9,017 shares issuable upon pre-funded warrant exercises.



Please wait processing your request...